Re: Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
posted on
Jul 08, 2019 09:54AM
GAC,
I think we are saying the same thing. We are both saying that we won't hear any results for any BETonMACE trial endpoint until the top-line data announcement.
"Of course we don't know what "selected" secondary endpoints might be released...I've been focused on secondary outcomes for CKD and Cognition. Are there others?"
Yes there are others. See here.
BDAZ